Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenomic biomarkers.

Sandra C Kirkwood1, Richard D Hockett

  • 1Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. skirkwood@lilly.com

Disease Markers
|October 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B-Cell Lymphomas.

Journal of clinical laboratory analysis·2026
Same author

Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies.

Oncotarget·2025
Same author

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.

Circulation·2009
Same author

Cytochrome p-450 polymorphisms and response to clopidogrel.

The New England journal of medicine·2008
Same author

4th US FDA-Drug Information Association pharmacogenomics workshop, held 10-12 December, 2007.

Pharmacogenomics·2008
Same author

Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia.

Journal of clinical psychopharmacology·2007
Same journal

RETRACTION: Pyrrosia petiolosa Extract Ameliorates Ethylene Glycol-Induced Urolithiasis in Rats by Inhibiting Oxidative Stress and Inflammatory Response.

Disease markers·2026
Same journal

Correction to "Estrogen Protects against Renal Ischemia-Reperfusion Injury by Regulating Th17/Treg Cell Immune Balance".

Disease markers·2026
Same journal

RETRACTION: miR-127-5p Targets JAM3 to Regulate Ferroptosis, Proliferation, and Metastasis in Malignant Meningioma Cells.

Disease markers·2026
Same journal

RETRACTION: Thyroxine Alleviates Energy Failure, Prevents Myocardial Cell Apoptosis, and Protects against Doxorubicin-Induced Cardiac Injury and Cardiac Dysfunction via the LKB1/AMPK/mTOR Axis in Mice.

Disease markers·2026
Same journal

RETRACTION: Kartogenin Induced Adipose-Derived Stem Cell Exosomes Enhance the Chondrogenic Differentiation Ability of Adipose-Derived Stem Cells.

Disease markers·2026
Same journal

Correction to "KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells".

Disease markers·2026
See all related articles

Pharmacogenomic biomarkers personalize medicine by predicting drug response. Rigorous studies are needed to validate genetic variants for clinical use, enabling tailored therapies and better patient outcomes.

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Pharmacogenomic biomarkers offer potential for personalized medicine and improved drug prescriptions.
  • Genetic biomarkers aid in understanding disease, identifying therapeutic targets, and classifying diseases molecularly.
  • Identifying drug activity biomarkers is crucial for stratifying individuals based on predicted therapeutic response, including efficacy and toxicity.

Purpose of the Study:

  • To highlight the critical role of pharmacogenomic biomarkers in advancing personalized medicine.
  • To outline the necessary scientific validation process for genetic biomarkers before widespread clinical application.
  • To emphasize the journey towards individualized therapy and improved clinical outcomes through pharmacogenomics.

Main Methods:

Related Experiment Videos

  • Identification of genetic variants and delineation of their functional significance in defined phenotypes.
  • Retrospective studies using stored or clinical trial samples to verify biomarker applicability.
  • Prospective clinical trials stratifying patients based on biomarkers to confirm population applicability and risk.

Main Results:

  • The development and application of pharmacogenomic biomarkers require extensive scientific investigation.
  • Validation involves both retrospective and prospective studies to ensure reliability and generalizability.
  • Understanding population applicability and associated risks is essential for clinical implementation.

Conclusions:

  • Pharmacogenomic biomarkers are key to personalized therapeutic interventions.
  • A rigorous, multi-step scientific process is required for biomarker validation and clinical integration.
  • The field is still in its early stages, with significant potential for future advancements in individualized therapy.